InnoCare Pharma Limited

Responsible Marketing Policy

1. Overview

This Policy aims to regulate the activities of InnoCare Pharma Limited (hereinafter referred to as the "Company") relating to the promotion, advertising and sales of products and services, medical communications, disease education and patient support worldwide, and to ensure that such activities comply with applicable laws and regulations, industry standards and business ethics, while providing stakeholders with information that is truthful, accurate, complete and balanced.

2 Scope of Application

This Policy applies to the Company's full-time, part-time, temporary and outsourced personnel, as well as distributors, agents, service providers and other business partners that conduct marketing, promotional, sales, meeting-related, patient service or digital communication activities on behalf of the Company.

3. Compliance with Laws, Regulations and Company Policies

All marketing activities conducted by the Company shall comply with applicable laws, regulations and industry standards relating to pharmaceutical administration, advertising, anti-unfair competition, anti-commercial bribery, data protection and other relevant matters in the jurisdictions where the Company operates, and shall be carried out in accordance with the Company's internal policies and procedures relating to approvals, expenses, meetings, sponsorships, third-party management and compliance. No personnel shall circumvent medical, legal and compliance, or other required approval procedures, nor shall compliance standards be compromised for reasons such as sales targets, business progress or any other considerations.

4. Accurate Disclosure of Product and Service Information

Information provided externally by the Company regarding products, diseases,

research and services shall be based on verified scientific evidence, regulatory approval documents and current and valid information. The Company shall ensure that accurate and complete product information is communicated to different audiences, including healthcare professionals (HCPs) and consumers. Such information shall include the applicable patient population, approved indications, conditions of use, efficacy, safety and important limitations. Concealment of known adverse reactions or other product-related risks is strictly prohibited, and product benefits and risks shall be presented in a balanced manner.

The Company prohibits false, exaggerated, vague, absolute or potentially misleading statements and shall not omit material information that may affect the audience's judgment. Product promotion shall not extend beyond the labelling, package inserts or scope of authorization approved by the relevant regulatory authorities. The Company shall not use any form of comparative advertising or mislead audiences through incomplete comparisons or disparaging statements.

5. Interactions with Healthcare Professionals, Patients and Patient Organizations

The Company's interactions with healthcare professionals, healthcare institutions, patients and patient organizations shall be based on genuine and reasonable scientific, educational, patient support or business needs and shall remain professional, transparent and independent. Such interactions shall not improperly influence prescribing, recommendations, procurement, market access, reimbursement or other commercial decisions in any manner.

Where consulting fees, speaker fees, research support, educational grants, meeting sponsorships, travel, meals or other transfers of value are provided to healthcare professionals or relevant institutions, there shall be a legitimate business basis, and such arrangements shall comply with requirements including reasonableness and necessity, fair market value, prior approval, complete record-keeping and compliant disclosure.

When cooperating with patient organizations, the Company shall clearly state the purpose of the cooperation, the Company's role, and any financial or in-kind support provided. The Company shall respect the independence of patient organizations and

shall not require them to provide improper endorsements or interfere with their organizational governance, expression of views or independent decision-making.

The Company and its third-party representatives shall not offer, promise, solicit or accept any improper benefit that may affect impartial judgment, including but not limited to kickbacks, cash, commissions, gifts, travel, entertainment, reimbursement of personal expenses, loans, employment arrangements, preferential treatment, or other pecuniary or non-pecuniary benefits.

6. Privacy Protection

The Company respects and protects the privacy and personal information of patients, healthcare professionals, customers and business partners. Such information shall be processed in accordance with the principles of lawfulness, legitimacy, necessity and data minimization, and shall not be disclosed, sold, exchanged or used beyond its originally specified purposes without lawful authorization.

7. Employee Training

The Company regularly provides responsible marketing training to relevant employees and ensures that training content, participant information and training completion records are properly maintained.

8. Reporting Channels for Violations

The Company encourages employees, customers, suppliers, patients, healthcare professionals, business partners and other third parties to promptly report any conduct that may violate marketing-related laws and regulations, industry standards, this Policy or other Company policies and procedures.

The Company shall register, assess and investigate reports received and, based on the findings of the investigation, take corrective actions, remediation measures, disciplinary actions or other necessary measures as appropriate. The Company protects the lawful rights and interests of whistleblowers, strictly prohibits the disclosure of their identities or specific details of their reports in any form, and strictly prohibits any form of discrimination or retaliation against whistleblowers.

Whistleblowers may report concerns to the Legal and Compliance Department of InnoCare through the following channels:

Reporting Email	legal_compliance@innocarepharma.com
Reporting Hotline	(010)66609747
Mailing Address	Legal and Compliance Department, InnoCare Pharma Limited Building 8, 8 Life Science Park Road, ZGC Life Science Park, Changping District, Beijing, PRC, 102206

9. Supervision and Audit

The Company shall include the implementation of the Responsible Marketing Policy within the scope of its audit and supervision activities, including but not limited to systematic internal reviews or audits of relevant activities and related expenditures. If any non-compliant marketing practice is identified, the Company shall take appropriate corrective measures and follow up on the completion of remediation actions.

10. Performance Tracking, Access and Revision

Based on management and disclosure needs, the Company shall track incidents involving non-compliance with requirements relating to product and service information and labelling, incidents involving non-compliance with marketing communication requirements, as well as monetary losses arising from legal proceedings relating to false or misleading marketing. Such information shall be disclosed, where appropriate, through the Company's ESG reports, annual reports or corporate website.

This Policy is available for review by the Company's employees. The Company shall periodically review this Policy in light of applicable laws and regulations, regulatory requirements, industry practices and changes in its business, and revise it where necessary.

This Policy shall take effect upon approval by the Company's authorized body. The latest version shall be published on the Company's official website at

(https://www.innocarepharma.com).